A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT With Brachytherapy in Patients With Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated With Androgen Deprivation

Trial Profile

A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT With Brachytherapy in Patients With Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated With Androgen Deprivation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs NBTXR 3 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Nanobiotix
  • Most Recent Events

    • 04 Apr 2017 Preliminary safety and feasibility data from this trial is expected in H2 2017, according to a Nanobiotix media release.
    • 31 May 2016 Status changed from planning to not yet recruiting, according to a Nanobiotix media release.
    • 29 Apr 2016 According to Nanobiotix media release, Nanobiotix received approval from the US Food and Drug Administration (FDA) for the Company's Investigational New Drug (IND) application on December 30, 2015 (announced January 2016). Company also plans to initiate this study in the US in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top